文献速递胸部肿瘤

基于前列腺、肺、结直肠和卵巢队列的血液生物标志物组合对肺癌死亡率的获益

Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
PubMed 文献 · J Clin Oncol · 2023-06-28

本研究利用前列腺、肺、结直肠和卵巢(PLCO)队列中552例肺癌病例和2193例非病例的诊断前血清,评估四标志物蛋白组合(4MP)联合PLCOm2012风险模型对致死性肺癌的识别效用。在1.0%和1.7%的6年风险阈值下,4MP+PLCOm2012风险评分高于1.0%阈值者的肺癌死亡累积发生率显著更高(P<.0001),亚分布风险比和肺癌死亡特异性风险比分别为9.88和10.65。结论认为该血液生物标志物组合联合PLCOm2012可识别致死性肺癌高危个体。

要点

  • 4MP+PLCOm2012模型预测肺癌死亡的AUC为0.88(95%CI 0.86-0.90)。
  • 评分高于1.0%6年风险阈值者肺癌死亡累积发生率显著更高(P<.0001)。
  • 测试阳性病例的亚分布HR为9.88(95%CI 6.44-15.18),肺癌死亡特异性HR为10.65(95%CI 6.93-16.37)。

核心结论

  • 基于血液的生物标志物组合联合PLCOm2012可识别致死性肺癌高危个体。

研究设计与样本

  • 研究使用PLCO队列中552例肺癌病例和2193例非病例的诊断前血清数据。
  • 采用已建立的逻辑回归模型,结合四标志物蛋白组合(4MP)与PLCOm2012风险模型。
  • 552例肺癌病例中387例(70%)死于肺癌。
  • 基于预设的1.0%和1.7%6年风险阈值计算肺癌死亡累积发生率、亚分布风险比和病因特异性风险比。

主要发现

  • 在采血后1年内诊断的病例和所有非病例中,4MP+PLCOm2012模型预测肺癌死亡的AUC为0.88(95%CI 0.86-0.90)。
  • 4MP+PLCOm2012评分高于1.0%6年风险阈值者的肺癌死亡累积发生率显著更高(modified χ2=166.27;P<.0001)。
  • 测试阳性病例的亚分布HR为9.88(95%CI 6.44-15.18),肺癌死亡特异性HR为10.65(95%CI 6.93-16.37)。

关键数值与推荐

  • 预设的1.0%和1.7%6年风险阈值分别对应现行和既往美国预防服务工作组筛查标准。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the utility of integrating a panel of circulating protein biomarkers in combination with a risk model on the basis of subject characteristics to identify individuals at high risk of harboring a lethal lung cancer. METHODS: Data from an established logistic regression model that combines four-marker protein panel (4MP) together with the Prostate, Lung, Colorectal, and Ovarian (PLCO) risk model (PLCOm2012) assayed in prediagnostic sera from 552 lung cancer cases and 2,193 noncases from the PLCO cohort were used in this study. Of the 552 lung cancer cases, 387 (70%) died of lung cancer. Cumulative incidence of lung cancer death and subdistributional and cause-specific hazard ratios (HRs) were calculated on the basis of 4MP + PLCOm2012 risk scores at a predefined 1.0% and 1.7% 6-year risk thresholds, which correspond to the current and former US Preventive Services Task Force screening criteria, respectively. RESULTS: When considering cases diagnosed within 1 year of blood draw and all noncases, the area under receiver operation characteristics curve estimate of the 4MP + PLCOm2012 model for risk prediction of lung cancer death was 0.88 (95% CI, 0.86 to 0.90). The cumulative incidence of lung cancer death was statistically significantly higher in individuals with 4MP + PLCOm2012 scores above the 1.0% 6-year risk threshold (modified χ2, 166.27; P < .0001). Corresponding subdistributional and lung cancer death-specific HRs for test-positive cases were 9.88 (95% CI, 6.44 to 15.18) and 10.65 (95% CI, 6.93 to 16.37), respectively. CONCLUSION: The blood-based biomarker panel in combination with PLCOm2012 identifies individuals at high risk of a lethal lung cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Irajizad E, Fahrmann JF, Marsh T, et al. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort. J Clin Oncol. 2023. PMID: 37379494. doi:10.1200/JCO.22.02424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。